Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

Persistence and pathogenesis of the neurotropic polyomavirus JC

(2015) Hassen S. Wollebo et al.   ANNALS OF NEUROLOGY

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

(2015) M. I. Domínguez-Mozo et al.   EUROPEAN JOURNAL OF NEUROLOGY

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

(2015) C McGuigan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients

(2014) Serena Delbue et al.   JOURNAL OF NEUROVIROLOGY

JC Virus Quasispecies Analysis Reveals a Complex Viral Population Underlying Progressive Multifocal Leukoencephalopathy and Supports Viral Dissemination via the Hematogenous Route

(2014) Tom Van Loy et al.   JOURNAL OF VIROLOGY

JC virus antibody status underestimates infection rates

(2013) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab

(2013) Maria Inmaculada Dominguez-Mozo et al.   Journal of Neuroimmune Pharmacology

Quasispecies Analysis of JC Virus DNA Present in Urine of Healthy Subjects

(2013) Tom Van Loy et al.   PLoS One

Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

(2013) Anna Bellizzi et al.   Virology Journal

Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification

(2012) A. Laroni et al.   Journal of Neuroimmune Pharmacology

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients

(2011) Carl E. Reid et al.   JOURNAL OF INFECTIOUS DISEASES

Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity

(2011) Leonid Gorelik et al.   JOURNAL OF INFECTIOUS DISEASES

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Structure-Function Analysis of the Human JC Polyomavirus Establishes the LSTc Pentasaccharide as a Functional Receptor Motif

(2010) Ursula Neu et al.   Cell Host & Microbe

Different patterns of BK and JC polyomavirus reactivation following renal transplantation

(2010) B. K. Saundh et al.   JOURNAL OF CLINICAL PATHOLOGY

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

(2010) L. Rinaldi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY